

Niiaz Khasanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6108957/publications.pdf>

Version: 2024-02-01

17
papers

9,537
citations

1162367

8
h-index

996533

15
g-index

19
all docs

19
docs citations

19
times ranked

10149
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	13.9	4,159
2	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	13.9	2,261
3	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
4	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
5	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
6	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , 2019, 394, 1169-1180.	6.3	155
7	Effects of the lercanidipine-“enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 139-148.	0.3	10
8	Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II. <i>Russian Journal of Cardiology</i> , 2019, 24, 7-16.	0.4	8
9	GENETIC AND FUNCTIONAL FACTORS IN THE DEVELOPMENT OF COGNITIVE IMPAIRMENT IN HYPERTENSION: A PROSPECTIVE STUDY. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2016, 8, 14-20.	0.2	4
10	PROGNOSTIC FACTORS AND LONGTERM SURVIVAL OF MYOCARDIAL INFARCTION PATIENTS, COMPLICATED BY EARLY RECURRENT ANGINA AND RENAL FUNCTION DECREASE. <i>Russian Journal of Cardiology</i> , 2016, , 66-69.	0.4	1
11	Family History of Cardiovascular Disease in Patients With Early Development of Acute Coronary Syndrome. <i>Kardiologiya</i> , 2018, 17, 12-17.	0.3	1
12	Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction. <i>Russian Journal of Cardiology</i> , 2020, 25, 4049.	0.4	1
13	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. <i>Russian Journal of Cardiology</i> , 2022, 26, 4791.	0.4	1
14	Visit-to-visit blood pressure variability in patients after acute coronary syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 206-215.	0.1	0
15	Features of sinus rhythm restoration in patients with paroxysmal and persistent non-valvular atrial fibrillation and previous COVID-19 infection in iron-deficiency anaemia. <i>Kazan Medical Journal</i> , 2022, 103, 54-62.	0.1	0
16	Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. <i>Russian Journal of Cardiology</i> , 2022, 26, 4807.	0.4	0
17	Rationale and design of the open-label, prospective, randomized study of the efficacy of intravenous versus oral iron deficiency therapy in improving left ventricular systolic function in patients with myocardial infarction (OPERA-MI). <i>Russian Journal of Cardiology</i> , 2022, 27, 4961.	0.4	0